• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巴西公共卫生系统中的卫生技术再评估:现状分析。

Health technology reassessment in the Brazilian public health system: Analysis of the current status.

机构信息

Faculty of Health Sciences, University of Brasília, Brasília, Brazil.

Oswaldo Cruz Foundation, Brasília, Brazil.

出版信息

PLoS One. 2019 Jul 29;14(7):e0220131. doi: 10.1371/journal.pone.0220131. eCollection 2019.

DOI:10.1371/journal.pone.0220131
PMID:31356609
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6663063/
Abstract

BACKGROUND

The reassessment of technologies and services offered by healthcare systems is recent initiative and still without a widely adopted and evaluated method. To a better understanding of this process in Brazil, we have described the health technology reassessment (HTR) performed by the National Committee for Health Technology Incorporation (Conitec) into Brazilian public health system (SUS).

METHODS

A documental, exploratory, descriptive, retrospective study with qualitative-quantitative approach regarding the HTR performed by Conitec from January 2012 to November 2017.

RESULTS

After applying the criteria of inclusion and exclusion, we selected 47 technologies for this study. The vast majority of the demands (41 demands) came from the public sector, and only six from the private sector. Most of the requests referred to the exclusion of specific indication; followed by extension of use, withdraw of the technology from SUS, maintenance, and restriction of use. The dimensions of analysis found in the recommendation reports were scientific evidence on efficacy, effectiveness and safety, disease-related issues, issues related to the use of technology, costs, and social participation. However, these dimensions were not included in all analysis, and a standardized structure of the reports has not been observed. The most relevant decision factors considered for decision-making were efficacy, safety and use of the technology.

CONCLUSION

During a six-year period of Conitec actuation, we could find some reassessments of technologies that are available in SUS. We observed that these activities had enabled progress, however, they are still not yet structured, with gaps in the selection process, and the assessment since no methodology and criteria for proper conduct were established.

摘要

背景

医疗保健系统提供的技术和服务的重新评估是最近的一项举措,仍然没有广泛采用和评估的方法。为了更好地了解巴西的这一过程,我们描述了国家卫生技术纳入委员会(Conitec)对巴西公共卫生系统(SUS)进行的卫生技术评估(HTR)。

方法

采用文件、探索性、描述性、回顾性研究方法,对 Conitec 于 2012 年 1 月至 2017 年 11 月进行的 HTR 进行了定性-定量研究。

结果

经过纳入和排除标准的应用,我们选择了 47 项技术进行本研究。绝大多数需求(41 项需求)来自公共部门,只有 6 项来自私营部门。大多数请求涉及特定适应症的排除;其次是扩大使用范围、将技术从 SUS 中撤出、维护和限制使用。在建议报告中发现的分析维度包括疗效、有效性和安全性、与疾病相关的问题、与技术使用相关的问题、成本和社会参与的科学证据。然而,并非所有分析都包含这些维度,也没有观察到报告的标准化结构。决策时考虑的最重要的决策因素是技术的疗效、安全性和使用。

结论

在 Conitec 运作的六年期间,我们发现了一些 SUS 中可用技术的重新评估。我们观察到这些活动取得了进展,但它们仍未结构化,在选择过程和评估中存在差距,因为没有建立适当行为的方法和标准。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a797/6663063/ee44ab2ae527/pone.0220131.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a797/6663063/ee44ab2ae527/pone.0220131.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a797/6663063/ee44ab2ae527/pone.0220131.g001.jpg

相似文献

1
Health technology reassessment in the Brazilian public health system: Analysis of the current status.巴西公共卫生系统中的卫生技术再评估:现状分析。
PLoS One. 2019 Jul 29;14(7):e0220131. doi: 10.1371/journal.pone.0220131. eCollection 2019.
2
Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations.巴西国家 HTA 机构决策过程面临的挑战:操作程序、证据使用和建议。
Health Res Policy Syst. 2018 May 11;16(1):40. doi: 10.1186/s12961-018-0319-8.
3
[The incorporation of nusinersen by the Brazilian Unified National Health System: critical thoughts on the institutionalization of health technology assessment in Brazil].[巴西统一国家卫生系统纳入诺西那生:对巴西卫生技术评估制度化的批判性思考]
Cad Saude Publica. 2019 Aug 29;35(8):e00099619. doi: 10.1590/0102-311X00099619.
4
Incorporation of new medicines by the National Commission for Incorporation of Technologies, 2012 to June 2016.技术纳入国家委员会对新药的纳入情况,2012年至2016年6月
Cien Saude Colet. 2017 Aug;22(8):2513-2525. doi: 10.1590/1413-81232017228.02002017.
5
[Multi-criteria decision analysis for health technology resource allocation and assessment: so far and so near?].[卫生技术资源分配与评估的多标准决策分析:现状与未来?]
Cad Saude Publica. 2017 Oct 26;33(10):e00045517. doi: 10.1590/0102-311X00045517.
6
Exploring the COVID-19 Pandemic's Impact on the Health Technology Assessment Process of the National Commission for the Incorporation of Technologies Into the Brazilian Health System.探索 COVID-19 大流行对巴西国家技术融入卫生系统委员会健康技术评估过程的影响。
Value Health Reg Issues. 2023 Sep;37:18-22. doi: 10.1016/j.vhri.2023.04.002. Epub 2023 May 15.
7
Health technology assessment in Brazil - an international perspective.巴西的卫生技术评估——国际视角
Cien Saude Colet. 2019 May 30;24(5):1709-1722. doi: 10.1590/1413-81232018245.17582017.
8
Horizon scanning in Brazil: outputs and repercussions.巴西的地平线扫描:产出与影响。
Rev Saude Publica. 2019 Nov 28;53:111. doi: 10.11606/S1518-8787.2019053001439. eCollection 2019.
9
Patient and public involvement in health technology decision-making processes in Brazil.巴西卫生技术决策过程中的患者和公众参与。
Rev Saude Publica. 2020 Dec 11;54:136. doi: 10.11606/s1518-8787.2020054002453. eCollection 2020.
10
Expert consensus (SBC/SBHCI) on the use of drug-eluting stents: recommendations of the Brazilian society of interventional cardiology/ Brazilian society of cardiology for the Brazilian public single healthcare system.药物洗脱支架使用的专家共识(SBC/SBHCI):巴西介入心脏病学会/巴西心脏病学会为巴西公共单一医疗体系提供的建议
Arq Bras Cardiol. 2006 Oct;87(4):e162-7. doi: 10.1590/s0066-782x2006001700037.

引用本文的文献

1
Stakeholders' perspectives on disinvestment of low-value healthcare interventions and practices in Malaysia: an online survey.利益相关者对马来西亚低价值医疗干预措施和实践的撤资看法:一项在线调查。
Int J Technol Assess Health Care. 2024 Nov 15;40(1):e57. doi: 10.1017/S0266462324004665.
2
The Critical Intersect of Regulations, Health Technology Assessment, and Drug Safety Assessments.法规、卫生技术评估和药物安全评估的关键交集。
Drug Saf. 2024 Apr;47(4):289-299. doi: 10.1007/s40264-023-01386-1. Epub 2023 Dec 19.
3
The challenges of implementing low-dose computed tomography for lung cancer screening in low- and middle-income countries.

本文引用的文献

1
Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency.新药价格谈判的决定因素。意大利药品管理局的经验。
Health Policy. 2019 Jun;123(6):595-600. doi: 10.1016/j.healthpol.2019.03.009. Epub 2019 Apr 13.
2
Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations.巴西国家 HTA 机构决策过程面临的挑战:操作程序、证据使用和建议。
Health Res Policy Syst. 2018 May 11;16(1):40. doi: 10.1186/s12961-018-0319-8.
3
The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil.
在低收入和中等收入国家实施低剂量计算机断层扫描进行肺癌筛查的挑战。
Nat Cancer. 2020 Dec;1(12):1140-1152. doi: 10.1038/s43018-020-00142-z. Epub 2020 Nov 30.
4
Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise.建立肿瘤药物国家再评估流程:加拿大癌症药物价值真实世界证据(CanREValue)合作组织通过模拟再评估练习所吸取的经验教训。
Curr Oncol. 2021 Nov 12;28(6):4645-4654. doi: 10.3390/curroncol28060392.
5
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group.制定重新评估流程的考量因素:来自加拿大癌症药物价值真实世界证据(CanREValue)合作组织重新评估与采用工作组的报告
Curr Oncol. 2021 Oct 16;28(5):4174-4183. doi: 10.3390/curroncol28050354.
6
A landscape analysis of health technology assessment capacity in the Association of South-East Asian Nations region.东南亚国家联盟地区卫生技术评估能力的态势分析
Health Res Policy Syst. 2021 Feb 11;19(1):19. doi: 10.1186/s12961-020-00647-0.
7
Using a Formal Strategy of Priority Setting to Mitigate Austerity Effects Through Gains in Value: The Role of Program Budgeting and Marginal Analysis (PBMA) in the Brazilian Public Healthcare System.利用优先级设定的正式策略,通过增加价值来缓解紧缩效应:在巴西公共医疗保健系统中,项目预算编制和边际分析(PBMA)的作用。
Appl Health Econ Health Policy. 2021 Jan;19(1):9-15. doi: 10.1007/s40258-020-00591-8.
巴西对用于治疗复发缓解型多发性硬化症的肌内干扰素β的去投资评估。
Pharmacoeconomics. 2018 Feb;36(2):161-173. doi: 10.1007/s40273-017-0579-0.
4
STATUS OF DISINVESTMENT INITIATIVES IN LATIN AMERICA: RESULTS FROM A SYSTEMATIC LITERATURE REVIEW AND A QUESTIONNAIRE.拉丁美洲撤资倡议现状:系统文献回顾和问卷调查的结果。
Int J Technol Assess Health Care. 2017 Jan;33(6):674-680. doi: 10.1017/S0266462317000812. Epub 2017 Sep 28.
5
DRUG DISINVESTMENT FRAMEWORKS: COMPONENTS, CHALLENGES, AND SOLUTIONS.药物停用框架:组成部分、挑战与解决方案。
Int J Technol Assess Health Care. 2017 Jan;33(2):261-269. doi: 10.1017/S0266462317000277. Epub 2017 Jul 13.
6
HEALTH TECHNOLOGY DISINVESTMENT WORLDWIDE: OVERVIEW OF PROGRAMS AND POSSIBLE DETERMINANTS.全球卫生技术撤资:计划概述及可能的决定因素。
Int J Technol Assess Health Care. 2017 Jan;33(2):239-250. doi: 10.1017/S0266462317000514. Epub 2017 Jul 3.
7
HEALTH TECHNOLOGY PERFORMANCE ASSESSMENT: REAL-WORLD EVIDENCE FOR PUBLIC HEALTHCARE SUSTAINABILITY.卫生技术绩效评估:公共医疗可持续性的真实世界证据。
Int J Technol Assess Health Care. 2017 Jan;33(2):279-287. doi: 10.1017/S0266462317000423. Epub 2017 Jun 23.
8
Sustainability in Health care by Allocating Resources Effectively (SHARE) 2: identifying opportunities for disinvestment in a local healthcare setting.通过有效分配资源实现医疗保健的可持续性(SHARE)2:确定在当地医疗环境中减少投资的机会。
BMC Health Serv Res. 2017 May 5;17(1):328. doi: 10.1186/s12913-017-2211-6.
9
Sustainability in Health care by allocating resources effectively (SHARE) 1: introducing a series of papers reporting an investigation of disinvestment in a local healthcare setting.通过有效分配资源实现医疗保健可持续性(SHARE)1:介绍一系列报告对当地医疗环境中撤资情况调查的论文。
BMC Health Serv Res. 2017 May 4;17(1):323. doi: 10.1186/s12913-017-2210-7.
10
A systematic review on current status of health technology reassessment: insights for South Korea.关于健康技术再评估现状的系统评价:对韩国的启示
Health Res Policy Syst. 2016 Nov 11;14(1):82. doi: 10.1186/s12961-016-0152-x.